US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Virtus LifeSci Biotech Clinical Trials ETF

48.61

-0.6395-1.30%

Post-market: 48.42-0.1869-0.38%19:35 EDT

Volume:9K

Turnover:451.66K

Market Cap:46.18M

PE:- -

High:49.12

Open:49.12

Low:48.33

Close:49.25

52wk High:56.18

52wk Low:24.54

Shares:950.00K

Float Shares:950.00K

Volume Ratio:0.49

T/O Rate:0.98%

Dividend:0.66

Dividend Rate:1.35%

ROE:--

ROA:--

PB:1.04

PE(LYR):- -

Loading ...

Overview Company News Filings

Alterity Therapeutics to Spotlight MSA Program at ASX SMIDcaps Conference

Shionogi’s Phase 3 COVID-19 Antiviral Trial Puts SGIOF Back in the Spotlight

TME Pharma CEO Emphasizes Cash Discipline and Strategic Partnering for Lead Cancer Asset

Mattel Enters Licensing Deal With BBC Studios Over Bluey Series Collection

MT Newswires Live

Mattel, BBC Studios announce multi-brand global licensing partnership for Bluey

10 Tuesday AM Reads

The Big Picture

SillaJen seeks approval for Phase 1 trial of Dexibuprofen injection

Syntara Sets 2026 AGM Date as It Refocuses on Fibrosis and Cancer Pipeline

AdAlta takes ‘East to West’ CAR-T strategy and EW-001 data to U.S. investors

Entropy Neurodynamics Reports Durable 12-Week Gains in BED Trial of Psychedelic Therapy TRP-8803

Dupixent’s Next Move: STYLE 1 Itch Study Wraps Up for Regeneron and Sanofi

GeoVax Updates Nasdaq Listing Amid Ongoing Clinical Progress

Psychedelic: Optimi to initiate Phase 2 trial of psilocybin-assisted therapy

Optimi Health to initiate Phase 2 trial of psilocybin-assisted therapy for MDD

Disc Medicine presents initial results from RESTORE phase 2 trial in PV patients

BioAge Labs doses first patient in QUELL-DME study

Bristol Myers’ arlocabtagene autoleucel shows positive results in Phase 2 trial

CARDIO-TTRansform Update: What Eplontersen’s Phase 3 Completion Means for AstraZeneca Investors

Alterity Therapeutics to Spotlight MSA Program at Cantor Global Healthcare Conference

AC Immune’s New Phase 1 NLRP3 Trial Puts Inflammation Strategy in Focus

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/BBC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BBC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBC\",,,,,undefined,":{"symbol":"BBC","market":"US","secType":"STK","nameCN":"Virtus LifeSci Biotech Clinical Trials ETF","latestPrice":48.6069,"timestamp":1789761600000,"preClose":49.2464,"halted":0,"volume":9298,"hourTrading":{"tag":"盘后","latestPrice":48.42,"preClose":48.6069,"latestTime":"19:35 EDT","volume":14,"amount":681.289,"timestamp":1789774511202,"change":-0.1869,"changeRate":-0.003845,"amplitude":0},"delay":0,"changeRate":-0.012985720783651154,"floatShares":950000,"shares":950000,"eps":0,"marketStatus":"Market Closed","change":-0.6395,"latestTime":"09-18 16:00:00 EDT","open":49.12,"high":49.12,"low":48.33,"amount":451662.734936,"amplitude":0.016042,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":49.2464,"sharesOutstanding":900004,"nav":49.294,"aum":46829269.03,"dividendRate":0.013482,"bidAskSpread":0.002154,"postHourTrading":{"tag":"盘后","latestPrice":48.42,"preClose":48.6069,"latestTime":"19:35 EDT","volume":14,"amount":681.289,"timestamp":1789774511202,"change":-0.1869,"changeRate":-0.003845,"amplitude":0},"volumeRatio":0.49175,"impliedVol":0.2995,"impliedVolPercentile":0.247},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBC\",,,,,undefined,":{"symbol":"BBC","floatShares":950000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.49175,"shares":950000,"dividePrice":0.6553,"high":49.12,"amplitude":0.016042,"preClose":49.2464,"low":48.33,"week52Low":24.54,"pbRate":"1.04","week52High":56.18,"institutionHeld":0,"latestPrice":48.6069,"eps":0,"divideRate":0.013482,"volume":9298,"delay":0,"ttmEps":0,"open":49.12,"prevYearClose":38.56,"prevWeekClose":49.3848,"prevMonthClose":53.05,"prevQuarterClose":52.6861,"fiveDayClose":49.3848,"twentyDayClose":53.8707,"sixtyDayClose":49.16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBC\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"BBC","amount":0.65544,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Virtus LifeSci Biotech Clinical Trials ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-29","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-29"},{"date":"2024-12-20","symbol":"BBC","amount":0.23947,"announcedDate":"2024-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-20","defaultRemindTime":1734705000000,"name":"Virtus LifeSci Biotech Clinical Trials ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-27","payableDate":"2024-12-20","currency":"USD","dateTimestamp":1734670800000,"payDate":"2024-12-27"},{"date":"2023-12-20","symbol":"BBC","amount":0.0823,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"Virtus LifeSci Biotech Clinical Trials ETF","recordDate":"2023-12-29","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-29"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBC\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-29","value":0.0823,"currency":"USD"},{"executeDate":"2024-12-20","recordDate":"2024-12-20","paymentDate":"2024-12-27","value":0.23947,"currency":"USD"},{"executeDate":"2025-12-22","recordDate":"2025-12-22","paymentDate":"2025-12-29","value":0.65544,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2668180509","title":"Alterity Therapeutics to Spotlight MSA Program at ASX SMIDcaps Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2668180509","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668180509?lang=en_us&edition=fundamental","pubTime":"2026-09-18 07:48","pubTimestamp":1789688927,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics ( ($AU:ATH) ) has shared an update. Alterity Therapeutics, a clinical-stage biotechnology company, develops disease-modifying...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-to-spotlight-msa-program-at-asx-smidcaps-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-to-spotlight-msa-program-at-asx-smidcaps-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FWD","AGNG","JDOC","DARP","XT","BBP","BK4585","BK4588","BK4007","LNGR","SYNB","RSPH","IEIH","IBB","BBC","FHLC","LENZ","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668999316","title":"Shionogi’s Phase 3 COVID-19 Antiviral Trial Puts SGIOF Back in the Spotlight","url":"https://stock-news.laohu8.com/highlight/detail?id=2668999316","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668999316?lang=en_us&edition=fundamental","pubTime":"2026-09-18 00:30","pubTimestamp":1789662653,"startTime":"0","endTime":"0","summary":"Shionogi & Co ($SGIOF) announced an update on their ongoing clinical study. Shionogi & Co. (SGIOF) is running a Phase 3 trial called “A Study of Se...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/shionogis-phase-3-covid-19-antiviral-trial-puts-sgiof-back-in-the-spotlight?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/shionogis-phase-3-covid-19-antiviral-trial-puts-sgiof-back-in-the-spotlight?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BNTX","SGIOF","BK4548","BK4535","BK4568","BK4588","BK4551","BK4007","BK4585","BBC","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667089246","title":"TME Pharma CEO Emphasizes Cash Discipline and Strategic Partnering for Lead Cancer Asset","url":"https://stock-news.laohu8.com/highlight/detail?id=2667089246","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667089246?lang=en_us&edition=fundamental","pubTime":"2026-09-16 14:37","pubTimestamp":1789540665,"startTime":"0","endTime":"0","summary":"TME Pharma N.V. ( ($FR:ALTME) ) has provided an announcement. TME Pharma, a clinical-stage biotech group developing therapies for brain cancer and ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tme-pharma-ceo-emphasizes-cash-discipline-and-strategic-partnering-for-lead-cancer-asset?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tme-pharma-ceo-emphasizes-cash-discipline-and-strategic-partnering-for-lead-cancer-asset?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DBB","TME","SG9999011746.SGD","NVIB","01698","BK4552","IE00BYQNZ168.SGD","IE00B12V2V27.USD","BK4565","IE00BYTNYN87.SGD","LU1023057109.AUD","LU0828238088.HKD","XBIX","BK4535","LU0509642566.USD","LU0359201612.USD","LU0359202008.SGD","BK4548","BK4563","LU2039709279.SGD","BK4108","BK4571","LU0269904917.USD","LU0456842615.SGD","BK4509","BK4531","BK4526","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667261656","title":"Mattel Enters Licensing Deal With BBC Studios Over Bluey Series Collection","url":"https://stock-news.laohu8.com/highlight/detail?id=2667261656","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667261656?lang=en_us&edition=fundamental","pubTime":"2026-09-16 00:27","pubTimestamp":1789489632,"startTime":"0","endTime":"0","summary":"Mattel  said Tuesday it entered a multi-year licensing deal with BBC Studios to bring the Bluey animation series through products from five of its franchises, starting this fall.The collection will feature characters from Bluey across Little People figures, Barbie accessories, Polly Pocket playsets, Hot Wheels vehicles, and UNO card games, according to a statement.Price: 13.54, Change: -0.49, Percent Change: -3.49","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7104","BK7507","BK4190","BK7506","MAT.AU","MAT","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667626951","title":"Mattel, BBC Studios announce multi-brand global licensing partnership for Bluey","url":"https://stock-news.laohu8.com/highlight/detail?id=2667626951","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667626951?lang=en_us&edition=fundamental","pubTime":"2026-09-16 00:05","pubTimestamp":1789488312,"startTime":"0","endTime":"0","summary":"Mattel (MAT) and BBC Studios announced a multi-year global licensing partnership that will bring Bluey to five of Mattel’s franchises. “Fans around...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mattel-bbc-studios-announce-multi-brand-global-licensing-partnership-for-bluey-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mattel-bbc-studios-announce-multi-brand-global-licensing-partnership-for-bluey-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","BK4190","MAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667662442","title":"10 Tuesday AM Reads","url":"https://stock-news.laohu8.com/highlight/detail?id=2667662442","media":"The Big Picture","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667662442?lang=en_us&edition=fundamental","pubTime":"2026-09-15 18:30","pubTimestamp":1789468243,"startTime":"0","endTime":"0","summary":"What if Elon Musk Was Always Elon Musk?The most disturbing part of the controversial new four-hour documentary. . Why So Many AI Researchers Think the Machines Could Kill Everyone: A combination of rapid advances, recursive self-improvement, and agentic swarms are genuinely “spooking people” inside big labs. Will Knight on Rishub Jain, who left Google DeepMind after realizing that using AI to build the next generation of AI was removing humans from the equation. see alsoAI Is Powerful Enough to Crack Our Hardest Math Problems — and Kill Us All: An Anthropic safety researcher puts the odds of annihilation above 10% — doomsday now more likely than Steph Curry missing a free throw. . ‘Offensively Cheap’: Solar Power Is Looking Up: Rachel Millard reports from Chakwal, Pakistan, where a cement maker is turning dry earth and peach groves into a forest of panels — solar already generates over a quarter of its power. . Video of the day: China Found Something Better Than Oil","market":"us","thumbnail":"https://ritholtz.com/wp-content/uploads/2030/07/headcount.png","type":0,"news_type":0,"thumbnails":["https://ritholtz.com/wp-content/uploads/2030/07/headcount.png"],"rights":{"source":"ritholtz_highlight","url":"https://ritholtz.com/2026/09/10-tuesday-am-reads-490/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://ritholtz.com/2026/09/10-tuesday-am-reads-490/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"ritholtz_highlight","symbols":["BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667261990","title":"SillaJen seeks approval for Phase 1 trial of Dexibuprofen injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2667261990","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667261990?lang=en_us&edition=fundamental","pubTime":"2026-09-15 13:46","pubTimestamp":1789451195,"startTime":"0","endTime":"0","summary":"SillaJen, Inc. ( ($KR:215600) ) has provided an announcement. SillaJen, Inc. has applied to Korea’s Ministry of Food and Drug Safety for approval t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sillajen-seeks-approval-for-phase-1-trial-of-dexibuprofen-injection?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sillajen-seeks-approval-for-phase-1-trial-of-dexibuprofen-injection?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667694618","title":"Syntara Sets 2026 AGM Date as It Refocuses on Fibrosis and Cancer Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2667694618","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667694618?lang=en_us&edition=fundamental","pubTime":"2026-09-15 08:16","pubTimestamp":1789431375,"startTime":"0","endTime":"0","summary":"Syntara Limited ( ($AU:SNT) ) has provided an update. Syntara Limited, an ASX-listed clinical-stage biotechnology company based in Sydney, develops...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/syntara-sets-2026-agm-date-as-it-refocuses-on-fibrosis-and-cancer-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/syntara-sets-2026-agm-date-as-it-refocuses-on-fibrosis-and-cancer-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","FHLC","BK4588","JDOC","AGNG","IBB","SYNB","IEIH","BK4585","DARP","RSPH","XT","FWD","LNGR","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667691804","title":"AdAlta takes ‘East to West’ CAR-T strategy and EW-001 data to U.S. investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2667691804","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667691804?lang=en_us&edition=fundamental","pubTime":"2026-09-15 07:16","pubTimestamp":1789427795,"startTime":"0","endTime":"0","summary":"The latest update is out from AdAlta Ltd. ( ($AU:1AD) ). AdAlta Limited, an Australian clinical-stage biotech specialising in cellular immunotherap...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/adalta-takes-east-to-west-car-t-strategy-and-ew-001-data-to-u-s-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/adalta-takes-east-to-west-car-t-strategy-and-ew-001-data-to-u-s-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","XBIX","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667576635","title":"Entropy Neurodynamics Reports Durable 12-Week Gains in BED Trial of Psychedelic Therapy TRP-8803","url":"https://stock-news.laohu8.com/highlight/detail?id=2667576635","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667576635?lang=en_us&edition=fundamental","pubTime":"2026-09-14 07:19","pubTimestamp":1789341541,"startTime":"0","endTime":"0","summary":"Tryptamine Therapeutics ( ($AU:ENP) ) has shared an update. Entropy Neurodynamics Limited, a clinical-stage biotech in Melbourne, is developing pre...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/entropy-neurodynamics-reports-durable-12-week-gains-in-bed-trial-of-psychedelic-therapy-trp-8803?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/entropy-neurodynamics-reports-durable-12-week-gains-in-bed-trial-of-psychedelic-therapy-trp-8803?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE000WXP2NQ0.USD","BBC","IE00BMG7P587.USD","BK4144","IE00BMG7P694.USD","IE000SL1IH01.SGD","IE00BD4GTW91.USD","IE00BMG7P702.HKD","XBIX","NVIB","TRP","IE00BD4GTV84.USD","EINC","TPYP","IE00BMG7P819.SGD","MLPX","IE000HOSIQF4.USD","IE00BD4GTT62.SGD","IE00BMG7P926.USD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666057576","title":"Dupixent’s Next Move: STYLE 1 Itch Study Wraps Up for Regeneron and Sanofi","url":"https://stock-news.laohu8.com/highlight/detail?id=2666057576","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666057576?lang=en_us&edition=fundamental","pubTime":"2026-09-12 00:30","pubTimestamp":1789144227,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals ($REGN), Sanofi ($SNYNF) announced an update on their ongoing clinical study. The STYLE 1 study is a Phase 3 trial run by...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/dupixents-next-move-style-1-itch-study-wraps-up-for-regeneron-and-sanofi?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/dupixents-next-move-style-1-itch-study-wraps-up-for-regeneron-and-sanofi?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNYNF","BK4007","PSIL","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666446516","title":"GeoVax Updates Nasdaq Listing Amid Ongoing Clinical Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2666446516","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666446516?lang=en_us&edition=fundamental","pubTime":"2026-09-11 05:02","pubTimestamp":1789074144,"startTime":"0","endTime":"0","summary":"The latest update is out from GeoVax Labs ( ($GOVX) ). GeoVax Labs, Inc., a clinical-stage biotechnology firm listed on Nasdaq as GOVX, develops va...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/geovax-updates-nasdaq-listing-amid-ongoing-clinical-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/geovax-updates-nasdaq-listing-amid-ongoing-clinical-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FWD","RSPH","LCLG","LNGR","PRGS","XT","IEIH","AGNG","LU2065732104.USD","IBB","BBC","DARP","BK4585","BBP","FHLC","BK4097","NQmain","JDOC","SYNB","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666659418","title":"Psychedelic: Optimi to initiate Phase 2 trial of psilocybin-assisted therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2666659418","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666659418?lang=en_us&edition=fundamental","pubTime":"2026-09-10 22:50","pubTimestamp":1789051821,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on study initiation plans, a Breakth...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/psychedelic-optimi-to-initiate-phase-2-trial-of-psilocybin-assisted-therapy-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/psychedelic-optimi-to-initiate-phase-2-trial-of-psilocybin-assisted-therapy-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666910405","title":"Optimi Health to initiate Phase 2 trial of psilocybin-assisted therapy for MDD","url":"https://stock-news.laohu8.com/highlight/detail?id=2666910405","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666910405?lang=en_us&edition=fundamental","pubTime":"2026-09-10 22:25","pubTimestamp":1789050337,"startTime":"0","endTime":"0","summary":"Optimi Health (OPTH) announces plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for individuals with maj...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/optimi-health-to-initiate-phase-2-trial-of-psilocybin-assisted-therapy-for-mdd-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/optimi-health-to-initiate-phase-2-trial-of-psilocybin-assisted-therapy-for-mdd-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","BBC","BK4007","NVIB","BK4139","IDNA","OPTH","PSIL","HYLG","ABVC","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666554185","title":"Disc Medicine presents initial results from RESTORE phase 2 trial in PV patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2666554185","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666554185?lang=en_us&edition=fundamental","pubTime":"2026-09-10 08:05","pubTimestamp":1788998708,"startTime":"0","endTime":"0","summary":"Disc Medicine (IRON) “presented positive initial results from the RESTORE-PV Phase 2 trial of DISC-3405 in patients with polycythemia vera. The dat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/disc-medicine-presents-initial-results-from-restore-phase-2-trial-in-pv-patients-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/disc-medicine-presents-initial-results-from-restore-phase-2-trial-in-pv-patients-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU0053671581.USD","BBC","IRON","PSIL","DISC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665037847","title":"BioAge Labs doses first patient in QUELL-DME study","url":"https://stock-news.laohu8.com/highlight/detail?id=2665037847","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665037847?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:35","pubTimestamp":1788870924,"startTime":"0","endTime":"0","summary":"BioAge Labs (BIOA) announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily o...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bioage-labs-doses-first-patient-in-quell-dme-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bioage-labs-doses-first-patient-in-quell-dme-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BIOA","BK4007","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665327821","title":"Bristol Myers’ arlocabtagene autoleucel shows positive results in Phase 2 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2665327821","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665327821?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:11","pubTimestamp":1788865885,"startTime":"0","endTime":"0","summary":"Bristol Myers (BMY) announced positive Phase 2 results from the registrational QUINTESSENTIAL trial of arlocabtagene autoleucel in adult patients w...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bristol-myers-arlocabtagene-autoleucel-shows-positive-results-in-phase-2-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bristol-myers-arlocabtagene-autoleucel-shows-positive-results-in-phase-2-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IHE","LU1670711123.USD","LU1032466523.USD","BK4559","LU1868837300.USD","LU0432979614.USD","LU1670710588.SGD","LU1868836914.USD","BK4585","LU1074936037.SGD","BBC","FTXH","LU0114720955.EUR","LU0321505868.SGD","LU0985481810.HKD","LU1236620834.HKD","BMY","IE00BJJMRZ35.SGD","LU1430594728.SGD","PSIL","LU0061475181.USD","LU2125154935.USD","LU0456855351.SGD","IE00BFTCPJ56.SGD","LU0882574055.USD","LU2360032135.SGD","LU0267386448.USD","LU1093756325.SGD","BK4588","LU0237698245.USD","LU2596442595.SGD","IE0002141913.USD","LU1261432733.SGD","LU1718418525.SGD","MYE","LU1093756168.USD","BK4534","IE00BSNM7G36.USD","LU0225284248.USD","LU1883839398.USD","LU1291159041.SGD","BK4126","IE0009355771.USD","LU1670710661.SGD","LU1989771016.USD","LU1983299246.USD","LU2133065610.SGD","LU2242652126.USD","LU1236620750.USD","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664338805","title":"CARDIO-TTRansform Update: What Eplontersen’s Phase 3 Completion Means for AstraZeneca Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2664338805","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664338805?lang=en_us&edition=fundamental","pubTime":"2026-09-04 00:30","pubTimestamp":1788453041,"startTime":"0","endTime":"0","summary":"AstraZeneca ($~AZN) announced an update on their ongoing clinical study. The CARDIO-TTRansform study is a Phase 3 trial that tests eplontersen in p...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cardio-ttransform-update-what-eplontersens-phase-3-completion-means-for-astrazeneca-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cardio-ttransform-update-what-eplontersens-phase-3-completion-means-for-astrazeneca-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BBC","ISBC","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664214842","title":"Alterity Therapeutics to Spotlight MSA Program at Cantor Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664214842","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664214842?lang=en_us&edition=fundamental","pubTime":"2026-09-03 07:47","pubTimestamp":1788392845,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics ( ($AU:ATH) ) has provided an update. Alterity Therapeutics, a clinical-stage biotechnology company developing disease-modify...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-to-spotlight-msa-program-at-cantor-global-healthcare-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-to-spotlight-msa-program-at-cantor-global-healthcare-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","BK4139","LENZ","JDOC","RSPH","LABU","BK4588","BK4539","FHLC","LNGR","LU0128526141.USD","HCSG","AGNG","BK4137","LU0029874061.USD","IBB","XT","BK4581","BBP","BK4007","DARP","BBC","IEIH","FWD","BK4585","SYNB","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664435478","title":"AC Immune’s New Phase 1 NLRP3 Trial Puts Inflammation Strategy in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2664435478","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664435478?lang=en_us&edition=fundamental","pubTime":"2026-09-03 00:31","pubTimestamp":1788366665,"startTime":"0","endTime":"0","summary":"AC Immune ($ACIU) announced an update on their ongoing clinical study. AC Immune SA is running a Phase 1 trial called a single-center, double-blind...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ac-immunes-new-phase-1-nlrp3-trial-puts-inflammation-strategy-in-focus?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ac-immunes-new-phase-1-nlrp3-trial-puts-inflammation-strategy-in-focus?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":1,"totalSize":144,"code":"91000000","status":"200"}]}}